Quality of Life in Adult Cancer Survivors (QLACS)

1. Abstract

The Quality of Life in Adult Cancer Survivors (QLACS) is a specialized, multidimensional psychometric instrument developed to evaluate the health-related quality of life (HRQoL) in individuals who have survived five or more years post-cancer diagnosis. Traditional oncology-focused patient-reported outcome measures (PROMs)—such as the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (FACT-G)—were predominantly engineered to capture acute toxicities, symptom burdens, and treatment-related functional impairments during active antineoplastic therapy. Consequently, these instruments demonstrate ceiling effects and conceptual deficits when applied to long-term cancer survivors who face persistent late effects, psychosocial re-entry hurdles, and existential renegotiations.

Developed by Nancy E. Avis and colleagues (2005), the QLACS fills this critical measurement void through a comprehensive 47-item architecture. The questionnaire evaluates 12 distinct domains structured into two overarching higher-order operational frameworks: seven generic domains (Negative Feelings, Positive Feelings, Cognitive Problems, Pain, Sexual Function, Energy/Fatigue, and Social Avoidance) and five cancer-specific domains (Financial Problems, Benefits of Cancer, Distress-Family, Appearance Concerns, and Distress-Recurrence). In some scoring configurations, sexual problems are further differentiated into Sexual Interest and Sexual Function. Respondents rate each item along a 7-point Likert-type frequency scale ranging from 1 (never) to 7 (always), assessing experiences over the preceding four weeks. Psychometric evaluations confirm robust internal consistency across all subscales (Cronbach’s α ≥ .72 to .91), stable construct validity through confirmatory factor analysis, and documented convergent and discriminant validity against established generic and oncology-specific measures. This profile renders the QLACS an essential tool for survivorship epidemiology, clinical long-term surveillance, and intervention trials.

2. Keywords

Quality of Life in Adult Cancer Survivors, QLACS, cancer survivorship, health-related quality of life, psychometrics, late effects, oncology PROMs, distress over recurrence, post-traumatic growth, long-term cancer survivors

3. Authors

The Quality of Life in Adult Cancer Survivors instrument was conceptualized, operationalized, and psychometrically validated by an interdisciplinary team of behavioral scientists, epidemiologists, and psychosocial oncologists:

• Nancy E. Avis, Ph.D. — Department of Social Sciences and Health Policy, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
• Kurt W. Smith, Ph.D. — New England Research Institutes (NERI), Watertown, Massachusetts, USA.
• Sarah McGraw, Ph.D. — New England Research Institutes (NERI), Watertown, Massachusetts, USA.
• R. Guy Smith, M.A. — New England Research Institutes (NERI), Watertown, Massachusetts, USA.
• Valerie M. Petronis, M.S. — New England Research Institutes (NERI), Watertown, Massachusetts, USA.
• Charles S. Carver, Ph.D. (1947–2019) — Department of Psychology, University of Miami, Coral Gables, Florida, USA; distinguished scholar in dispositional optimism, coping processes, and behavioral self-regulation in oncology.

4. Purpose

The primary clinical and epidemiological objective of the QLACS is the comprehensive, standardized measurement of physical, cognitive, psychosocial, and economic health status in adult cancer survivors who have passed the acute phase of treatment—specifically individuals five or more years post-diagnosis. Breakthroughs in systemic antineoplastic regimens, surgical techniques, targeted biologics, and multimodal radiotherapy have led to substantial improvements in five-year and ten-year survival rates across solid and hematologic malignancies. However, the expanding population of cancer survivors experiences a constellation of chronic sequelae, often termed “late effects” and “long-term effects.” These sequelae include accelerated physiological aging, anthracycline-induced cardiotoxicity, persistent taxane- and platinum-induced peripheral neuropathy, secondary lymphedema, chronic fatigue, structural cognitive deficits (“chemobrain”), sexual dysfunction, fear of cancer recurrence (FCR), and socioeconomic toxicity.

Historically, researchers and clinical teams utilized generic HRQoL tools such as the Medical Outcomes Study 36-Item Short Form Survey (SF-36) or acute oncology questionnaires such as the EORTC QLQ-C30. Although generic scales permit direct normative comparisons with non-cancer control populations, they lack content validity regarding cancer-specific survivorship challenges, such as the persistent dread of disease relapse or body image disturbances caused by surgical scarring or reconstructive failure. Conversely, acute oncology measures focus on nausea, acute emesis, and severe physical functional limitations, generating pronounced ceiling effects among long-term survivors who have regained basic functional independence yet continue to experience subtle, multidimensional quality-of-life impairments.

The QLACS resolves this dilemma by incorporating both generic and cancer-specific domains within a single psychometrically balanced battery. The instrument fulfills three distinct methodological applications:

• Comparative Population Surveillance: The seven generic domains enable direct benchmarking between long-term cancer survivors and matched non-cancer reference cohorts, isolating the excess burden of morbidity attributable to prior neoplastic disease.
• Longitudinal Survivorship Cohort Studies: The five cancer-specific domains monitor the trajectory of late psychological, financial, and relational consequences over decades, capturing both enduring vulnerabilities and potential post-traumatic growth.
• Interventional Trial Evaluation: The QLACS serves as an outcome measure for behavioral, pharmacological, and lifestyle interventions targeting chronic fatigue, physical rehabilitation, cognitive remediation, and recurrence-related existential anxiety.

5. Psychological Construct

The conceptual framework of the QLACS defines cancer survivorship quality of life as an intrinsically multidimensional, subjective, and dynamic construct. Rather than conceptualizing QoL merely as the absence of illness or symptom remission, the instrument operationalizes HRQoL across twelve distinct primary subscales, organized under two overarching domains: Generic Quality of Life and Cancer-Specific Quality of Life.

Generic Quality of Life Subscales

The generic subscales represent general dimensions of physical, psychological, and social functioning that are relevant to any adult population, regardless of disease status:

• Negative Feelings (4 items): Assesses non-specific depressive symptoms, anxiety, psychological distress, dysphoria, and emotional lability experienced over the previous month (e.g., feeling blue, anxious, or burdened by mood swings).
• Positive Feelings (4 items): Evaluates positive psychological functioning, subjective well-being, life satisfaction, and optimism (e.g., feeling happy, enjoying life, and maintaining a positive outlook).
• Cognitive Problems (4 items): Quantifies subjective complaints of cognitive dysfunction, focusing on working memory, executive processing, attention span, and distractibility—often associated with post-chemotherapy cognitive impairment.
• Pain (4 items): Gauges the severity of bodily aches, chronic discomfort, and the degree to which persistent physical pain impairs mood, daily activities, and social functioning.
• Energy / Fatigue (4 items): Captures the spectrum of physical vitality versus cancer-related fatigue, contrasting subjective vigor against persistent feelings of exhaustion that are unrelieved by rest.
• Sexual Function and Sexual Interest (2 to 4 items): Assesses disruptions in sexual performance, dissatisfaction with sexual activity, and loss of libido. Depending on scoring models, these items are interpreted as a single consolidated dimension or as two interrelated sub-domains.
• Social Avoidance (4 items): Examines behavioral withdrawal, reluctance to initiate new interpersonal connections, and conscious avoidance of established social networks or gatherings.

Cancer-Specific Quality of Life Subscales

The cancer-specific subscales capture long-term consequences linked to the diagnosis, treatment, and ongoing legacy of cancer:

• Financial Problems (4 items): Measures subjective financial toxicity resulting from cumulative out-of-pocket medical bills, insurance denial, uncompensated leave, or permanent loss of employment and earning capacity.
• Benefits of Cancer (4 items): Reflects concepts of post-traumatic growth and benefit finding. It evaluates whether the experience of surviving a life-threatening illness fostered enhanced personal resilience, re-prioritized life values, and deepened appreciation for daily existence.
• Distress-Family (3 items): Measures vicarious familial anxiety, specifically worrying that biological relatives face heightened hereditary susceptibility to malignancy, need genetic screening, or carry oncogenic mutations.
• Appearance Concerns (4 items): Evaluates body image dissatisfaction, embarrassment regarding treatment-induced physical changes (e.g., surgical scars, mastectomy, amputations, persistent alopecia, radiation dermatitis), and perceived social stigmatization.
• Distress-Recurrence (4 items): Evaluates fear of cancer recurrence (FCR), preoccupation with potential relapse, somatic hypervigilance (e.g., misinterpreting benign physical sensations as evidence of malignancy), and existential distress regarding cancer-related mortality.

6. Theoretical Framework

The architectural foundation of the QLACS integrates multiple theoretical paradigms across health psychology, behavioral medicine, and psychometrics, drawing primarily on the Wilson and Cleary Model of Patient Outcomes, Lazarus and Folkman’s Transactional Model of Stress and Coping, and Carver and Scheier’s Cybernetic Model of Behavioral Self-Regulation.

The Wilson and Cleary Conceptual Taxonomy

The Wilson and Cleary (1995) health-related quality of life taxonomy links biological and physiological variables, symptom status, functional status, general health perceptions, and overall QoL. The QLACS operationalizes this continuum by addressing the transition from primary physiological insult (neoplasia and toxic therapy) into persistent symptom status (chronic pain, fatigue, cognitive haze) and functional decrements (interpersonal withdrawal, sexual difficulties). Most importantly, the cancer-specific subscales examine how individual characteristics (e.g., cognitive appraisal of bodily sensations) and environmental characteristics (e.g., financial resources, familial context) shape broader health perceptions and existential evaluations.

Cognitive Appraisal and the Transactional Coping Model

Under the Transactional Model of Stress and Coping (Lazarus & Folkman, 1984), long-term survivorship represents a chronic, low-intensity stressor punctuated by acute triggers (e.g., surveillance scans, physician visits, unexplained aches). Primary appraisal determines whether an event or somatic sensation is categorized as benign, irrelevant, or life-threatening. The Distress-Recurrence subscale directly reflects catastrophic primary appraisals, wherein ordinary physical sensations trigger acute mortality salience. Conversely, secondary appraisal evaluates one’s coping resources; the Benefits of Cancer subscale measures cognitive reframing, positive reappraisal, and meaning-making, capturing the dialectical tension between vulnerability and resilience.

Self-Regulation and Benefit Finding

Co-developer Charles S. Carver contributed extensive theoretical insights regarding cybernetic self-regulation and dispositional optimism in chronic illness. Carver and Scheier posited that when individuals encounter profound disruptions to fundamental life trajectories, such as a cancer diagnosis, they experience substantial disequilibrium. Re-establishing equilibrium requires recalibrating personal goals, adjusting behavioral feedback loops, and engaging in cognitive adaptation. The presence of the Benefits of Cancer domain alongside traditional deficit-focused indices acknowledges that psychological adaptation is non-linear: survivors can experience persistent distress alongside genuine post-traumatic psychological growth.

7. Validity

The validation of the QLACS followed a systematic multistep process characterized by high methodological rigor, moving from qualitative content generation through extensive empirical field testing.

Content and Construct Validity

Content validity was established through preliminary in-depth qualitative interviews conducted with 59 long-term cancer survivors across various primary tumor types. This qualitative phase ensured that item generation reflected survivor-identified priorities rather than clinician-assumed concerns. The initial item pool was subsequently refined, field-tested, and administered to an independent validation cohort of 242 long-term cancer survivors (Avis et al., 2005). Exploratory and confirmatory factor analyses verified that the 12 domains maintained construct independence, demonstrating that generic physical and psychological functioning represent distinct conceptual spaces from cancer-specific existential and appearance concerns.

Convergent and Discriminant Validity

Convergent validity was evaluated by correlating QLACS subscales against legacy measurement systems, including the SF-36 Health Survey, the Center for Epidemiologic Studies Depression Scale (CES-D), the State-Trait Anxiety Inventory (STAI), and the Impact of Event Scale (IES):

• Generic Domains: Showed strong convergent validity, with bivariate correlations exceeding .72 between QLACS subscales and corresponding criterion constructs (e.g., QLACS Energy/Fatigue correlated strongly with SF-36 Vitality; QLACS Pain correlated with SF-36 Bodily Pain; QLACS Negative Feelings correlated with CES-D and STAI). An exception was observed in the Social Avoidance subscale, which demonstrated moderate correlations (~.50 to .65) with generic social functioning indices, reflecting its specific focus on interpersonal withdrawal rather than broad functional limitation.
• Cancer-Specific Domains: Demonstrated discriminant divergence from generic physical and functional measures, confirming that cancer-specific indices measure unique psychological variance. For example, Distress-Recurrence correlated moderately with IES Intrusion and STAI-Trait Anxiety, yet maintained minimal correlation with physical function metrics, confirming its distinct affective nature.
• Known-Groups Validity: The QLACS successfully distinguished between survivors who underwent intensive multimodal therapies versus those receiving local treatments alone. It also differentiated between patients with recurrent diagnostic evaluations and those with uneventful survivorship trajectories.

8. Reliability

Psychometric evaluations across multiple independent international cohorts demonstrate that the QLACS exhibits high scale reliability across both generic and disease-specific domains.

Internal Consistency

In the primary validation study by Avis et al. (2005), internal consistency was calculated using Cronbach’s alpha across all 12 individual domain subscales. Every subscale met or exceeded the accepted psychometric benchmark of .70 for research instruments, with several exceeding .85:

• Generic Subscales: Alpha coefficients ranged from .72 to .91 (e.g., Negative Feelings α ≈ .88; Positive Feelings α ≈ .86; Cognitive Problems α ≈ .84; Pain α ≈ .85; Energy/Fatigue α ≈ .87; Social Avoidance α ≈ .79).
• Cancer-Specific Subscales: Alpha coefficients ranged from .74 to .90 (e.g., Financial Problems α ≈ .89; Benefits of Cancer α ≈ .83; Distress-Family α ≈ .74; Appearance Concerns α ≈ .81; Distress-Recurrence α ≈ .86).

Temporal Stability (Test-Retest Reliability)

Subsequent psychometric investigations evaluating the temporal stability of the QLACS across two-to-four-week intervals in clinically stable cohorts revealed intraclass correlation coefficients (ICCs) ranging from .76 to .89 across the generic and cancer-specific domains. These findings indicate that while the instrument captures fluctuations in affective states, it maintains solid measurement stability over time in the absence of clinical events.

9. Factor Analysis

The structural dimensionality of the QLACS was evaluated using both exploratory factor analysis (EFA) during scale construction and confirmatory factor analysis (CFA) during formal validation.

Exploratory Factor Structure

During the developmental phase, an initial pool of over 100 items derived from qualitative interviews was subjected to principal components analysis (PCA) with oblique (Promax) rotation, allowing underlying dimensions to correlate naturally. Items demonstrating low primary factor loadings (< .45), high cross-loadings (≥ .30 on secondary factors), or ambiguous semantic alignment were iteratively removed. This procedure yielded the stable 12-factor primary structure.

Confirmatory Factor Analysis and Second-Order Architecture

Confirmatory factor models tested the fit of the 12 primary factors nested within two overarching second-order latent constructs: Generic Summary HRQoL and Cancer-Specific Summary HRQoL.

• Factor Loadings: Standardized factor loadings across all individual items onto their respective primary latent dimensions consistently exceeded .60 (ranging between .61 and .92), demonstrating robust indicator reliability.
• Model Fit Indices: Structural equation modeling demonstrated satisfactory goodness-of-fit for the hierarchical model, with Comparative Fit Index (CFI) > .90, Tucker-Lewis Index (TLI) > .90, and Root Mean Square Error of Approximation (RMSEA) ≤ .055 (90% CI: .049–.061).
• Cross-Cultural Factor Invariance: International cross-cultural adaptation studies (e.g., Spanish, Chinese, Dutch, and Danish adaptations) have corroborated the stability of this 12-factor architecture, confirming metric and scalar invariance across diverse survivor cohorts.

10. Instrument / Measurement Tool

The operational administration parameters and structural properties of the QLACS are detailed below:

• Instrument Type: Multidimensional Patient-Reported Outcome Measure (PROM) / Self-report psychological questionnaire.
• Administration Modality: Paper-and-pencil self-administration, interactive electronic clinical outcome assessment (eCOA), or structured research interview.
• Target Population: Adult cancer survivors (≥ 18 years of age) who are ≥ 5 years post-cancer diagnosis.
• Total Item Count: 47 individual items (numbered sequentially 1 through 28 for generic domains, followed by an introductory transitional prompt, and items 29 through 47 for cancer-specific domains).
• Recall Period: Past 4 weeks (“In the past 4 weeks…”).
• Response Format: 7-point Likert-type frequency scale:
  • 1 = Never
  • 2 = Seldom
  • 3 = Sometimes
  • 4 = About as often as not
  • 5 = Frequently
  • 6 = Very often
  • 7 = Always
• Subscale Item Composition:
  • Negative Feelings: Items 7, 9, 19, 24
  • Positive Feelings: Items 6, 8, 22, 28
  • Cognitive Problems: Items 2, 3, 4, 23
  • Pain: Items 13, 17, 21, 27
  • Sexual Interest: Items 16, 26
  • Energy/Fatigue: Items 1 (reverse-scored), 5, 11, 14
  • Sexual Function: Items 10, 12
  • Social Avoidance: Items 15, 18, 20, 25
  • Financial Problems: Items 30, 37, 43, 45
  • Benefits of Cancer: Items 29, 32, 40, 41
  • Distress-Family: Items 31, 34, 42
  • Appearance Concerns: Items 33, 35, 38, 44
  • Distress-Recurrence: Items 36, 39, 46, 47
• Scoring and Transformation Procedures:
  • Reverse Coding: Item 1 (“You had the energy to do the things you wanted to do”) must be reverse-coded (1=7, 2=6, 3=5, 4=4, 5=3, 6=2, 7=1) prior to calculating the Energy/Fatigue subscale score.
  • Subscale Scores: Computed by summing item responses within each domain and dividing by the number of answered items, yielding a mean domain score ranging from 1 to 7. Alternatively, raw summation can be used. Higher scores on symptom/problem subscales denote greater impairment, distress, or frequency of symptoms. Conversely, higher scores on Positive Feelings and Benefits of Cancer represent higher levels of well-being and positive cognitive appraisal.
  • Summary Scores: A Generic Summary Score can be derived by calculating the mean of the 7 generic subscales (with Positive Feelings reverse-scored if an overall impairment index is desired). A Cancer-Specific Summary Score is obtained by averaging the cancer-specific subscale scores (typically excluding or examining the Benefits subscale separately, as post-traumatic growth correlates differently with psychological distress).
• Estimated Completion Time: 10 to 15 minutes.

11. Permissions & Fee and Test Year

The Quality of Life in Adult Cancer Survivors (QLACS) was published in 2005 by Nancy E. Avis and colleagues in the peer-reviewed journal Quality of Life Research. The instrument was placed in the public domain for academic, non-commercial research, and non-funded clinical surveillance purposes to promote survivorship research.

Researchers and healthcare systems wishing to use the QLACS in non-commercial contexts may typically administer the tool without licensing fees, provided proper bibliographic citation is maintained. Investigators planning to utilize the scale in commercially funded clinical trials, pharmaceutical sponsored studies, or proprietary digital health platforms should contact the corresponding author, Dr. Nancy E. Avis, at Wake Forest University School of Medicine, to discuss formal licensing terms and electronic implementation permissions.

12. References

Below is a curated list of foundational peer-reviewed literature detailing the conceptualization, validation, and clinical application of the QLACS and related constructs:

• Avis, N. E., Smith, K. W., McGraw, S., Smith, R. G., Petronis, V. M., & Carver, C. S. (2005). Assessing quality of life in adult cancer survivors (QLACS). Quality of Life Research, 14(4), 1007–1023. https://doi.org/10.1007/s11136-004-2147-2
• Carver, C. S. (2005). Assessing quality of life in adult cancer survivors: What have we learned? Quality of Life Research, 14(4), 1025–1028. https://doi.org/10.1007/s11136-004-2148-1
• Lazarus, R. S., & Folkman, S. (1984). Stress, appraisal, and coping. Springer Publishing Company.
• Mols, F., Vingerhoets, A. J., Coebergh, J. W., & van de Poll-Franse, L. V. (2005). Quality of life in long-term cancer survivors awarded: A systematic review of population-based studies. European Journal of Cancer, 41(17), 2610–2619. https://doi.org/10.1016/j.ejca.2005.08.027
• Pearman, T. (2003). Quality of life and psychosocial adjustment in gynecologic cancer survivors. Health and Quality of Life Outcomes, 1, Article 33. https://doi.org/10.1186/1477-7525-1-33
• Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA, 273(1), 59–65. https://doi.org/10.1001/jama.1995.03520250075037

13. Items of the Scale (Questionnaire)